Buscar en
Archivos de la Sociedad Española de Oftalmología (English Edition)
Toda la web
Inicio Archivos de la Sociedad Española de Oftalmología (English Edition) Intravitreal bevacizumab for choroidal neovascularization associated with Best&#...
Journal Information
Vol. 89. Issue 10.
Pages 405-407 (October 2014)
Share
Share
Download PDF
More article options
Visits
1375
Vol. 89. Issue 10.
Pages 405-407 (October 2014)
Short communication
Intravitreal bevacizumab for choroidal neovascularization associated with Best's disease
Bevacizumab intravítreo en neovascularización coroidea asociada a enfermedad de Best
Visits
1375
D. Velazquez-Villoria
Corresponding author
dvvilloria@alumni.unav.es

Corresponding author.
, C. Macià Badia, J. Rigo Quera, L. Velez-Escola, G. Arcos-Algaba, V. Martínez-Castillo, J. García-Arumí
Servicio de Oftalmología, Hospital Vall d’Hebrón, Barcelona, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (6)
Show moreShow less
Abstract
Case report

A 27-year-old woman presented with loss of vision in the right eye (20/200). Ophthalmoscopic examination showed intraretinal hemorrhage in the macular region with neurosensory detachment in the right eye, and viteliform deposit in the left eye. Fluorescein angiography and the electrooculogram confirmed the diagnosis of choroidal neovascularization associated with Best's disease. Four weeks after a single bevacizumab intravitreal injection, visual acuity was restored (20/25) and remained stable after a 12 month follow-up.

Discussion

Intravitreal bevacizumab appears to be an effective treatment for choroidal neovascularization associated to Best's disease.

Keywords:
Best's disease
Best's vitelliform macular dystrophy
Choroidal neovascularization
Bevacizumab
Intravitreal injection
Resumen
Caso clínico

Mujer de 27 años que presentaba disminución de visión en ojo derecho (20/200). El examen funduscópico reveló una hemorragia intraretiniana macular con desprendimiento neurosensorial en ojo derecho, y un depósito de material viteliforme en el ojo izquierdo. La angiografía fluoresceínica y el electrooculograma confirmaron el diagnóstico de neovascularización coroidea asociada a enfermedad de Best. Cuatro semanas después de una única inyección de bevacizumab intravítreo, la agudeza visual a la normalidad (20/25) y se mantuvo estable tras 12 meses de seguimiento.

Discusión

El bevacizumab intravítreo puede ser una opción terapéutica eficaz en la neovascularización coroidea secundaria a enfermedad de Best.

Palabras clave:
Enfermedad de Best
Distrofia macular viteliforme de Best
Neovascularización coroidea
Bevacizumab
Inyección intravítrea

Article

These are the options to access the full texts of the publication Archivos de la Sociedad Española de Oftalmología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Archivos de la Sociedad Española de Oftalmología (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos